Rock Springs Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
– Sell
-157,900
Closed -$9.98M – 156
2021
Q2
$9.98M Buy
+157,900
New +$8.15M 0.2% 115

Other funds holding APLS

Rock Springs Capital Management's APLS Position: Q2 2026 in Review

Rock Springs Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 162,750 shares — an estimated $6.55M sold.

Rock Springs Capital Management first reported a position in APLS in Q3 2021 and held it in 9 quarters. The position peaked at $6.55M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Rock Springs Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Rock Springs Capital Management sold 162,750 Apellis Pharmaceuticals shares in Q2 2026, an estimated $6.55M.
  • Rock Springs Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 9 quarters.
  • Rock Springs Capital Management's Apellis Pharmaceuticals position peaked at $6.55M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.